Search
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It was first approved by the FDA in 2013. Macitentan differs from its predecessor bosentan in part due to its lower risk ...
TRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigationalisolated from an HLA-matched donor's mobilized peripheral blood — purified hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcons) — administered as
Sulfacytine
go.drugbank.com/drugs/DB01298ApprovedSulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle.
CIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)
ND1251
go.drugbank.com/drugs/DB05132ExperimentalND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and certain respiratory diseases.
Anti-SARS-CoV-2 equine immunoglobulin fragments
go.drugbank.com/drugs/DB16368InvestigationalAnti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine
Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalIt antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.
ECT-001 expanded cord blood
go.drugbank.com/drugs/DB21745Investigational[L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.
TA-NIC
go.drugbank.com/drugs/DB05445InvestigationalTA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients.
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalIt is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis